|Day Low/High||0.00 / 9.71|
|52 Wk Low/High||0.00 / 10.20|
Pfizer has dominated headlines this year with its failed Allergan merger and its Anacor Pharmaceuticals purchase.
It is hard to see much growth in the market overall, until earnings growth returns.
Jim Cramer says he wouldn't be surprised if Allergan looked at buying Anacor before Pfizer decided to acquire the company for $5.2 billion, including debt.
U.S. stocks opened higher on Monday, amid rising oil prices.
Investors rushed to the Palo Alto, Calif.-based drugmaker on news of Pfizer's generous takeover valuation.
Shares appear ready to push forward after three months of consolidating.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
As M&A action heats up in the sector, consider two names that could shape up to be prime targets.